In adults with type 2 diabetes, pharmaceutical targeting of renal glucose reabsorption by inhibition of SGLT2 can be successful at improving glycaemic control via excretion of glucose in urine (26). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.